American CryoStem Corporation Appoints Nobel Prize Nominee And One Of The Leading Stem Cell Experts Vincent C. Giampapa, M.D. To Its Medical And Scientific Advisory Board
EATONTOWN, NJ--(Marketwired - April 14, 2016) - American CryoStem Corporation (OTC PINK: CRYO), a leading developer and marketer of patented adipose tissue-based cellular technologies for the regenerative and personalized medicine industries with laboratories in New Jersey, and licensed labs in Tokyo, Hong Kong and Shenzhen, China, today announced it has appointed Vincent C. Giampapa, M.D., F.A.C.S. to the Company's Medical and Scientific Advisory Board. In this capacity, he will have an active role assisting the Company with the development of its "From laboratory to clinic/physician's office" services and applications platform.
Dr. Giampapa recently received a nomination for the Nobel Prize for his groundbreaking stem cell research related to the new science of Epigenetics, which studies science's ability to help optimize human cell function so that people age better. He is an accomplished entrepreneur, Board Certified in Plastic and Reconstructive Surgery, and the founder/director of Plastic Surgery Center International as well as The Giampapa Institute for Anti-Aging Medical Therapy and the Regenerative Medicine Institute located in Costa Rica. He is the author of the only medical textbook on Anti-Aging Medicine and Age Management for physicians, and has published five books on anti-aging and genetics in addition to numerous articles in academic journals.
John S. Arnone, American CryoStem CEO, stated, "Dr. Giampapa brings a wealth of industry experience and technical expertise to help guide our long-term success in the rapidly developing global adipose tissue-derived stem cell market. His industry recognition as one of the world's leading authorities on stem cell applications, along with his global contacts throughout the industry is an invaluable asset to the company as we look to build upon our foothold in the Asian and North American marketplace.
"We plan to expand our North American operations and our international laboratory licensing platform of regional labs in Asia and into Latin America as well as leverage the territories by adding incremental services and product lines for our proprietary mediums and stem cell applications. Dr. Giampapa is ideally qualified to help lead this and other corporate development initiatives. I'm delighted to welcome him to American CryoStem," concluded Mr. Arnone.
Commenting on his appointment, Dr. Giampapa said, "As the regenerative medicine industry expands, American CryoStem's methodology and market leading state-of-the-art stem cell products and services makes its collection-processing-storage platform the gold standard of stem cell banking service providers. I am excited to have the opportunity to contribute to American CryoStem's success."
About Vincent C. Giampapa, M.D., F.A.C.S.
Dr. Giampapa is Board Certified in Plastic and Reconstructive Surgery and Anti-Aging, and the founder/director of Plastic Surgery Center International, The Giampapa Institute for Anti-Aging Medical Therapy, and the Regenerative Medicine Institute located in Costa Rica. He is a co-founder of The Academy of Anti-Aging Medicine (A4M), comprised of over 26,000 members representing over 110 nations, the first president of the Board of Anti-Aging Medicine and the founder of healthycell®, an advanced cell health nutritional supplement and StemBank™, a blood derived stem cell extraction and storage company. He is a Fellow of the American College of Surgeons, and has served as Research Fellow for such other prestigious institutes as Columbia Presbyterian Medical Center in New York City, and as the Director of Microsurgery and Re-plantation Surgery at the University of Medicine and Dentistry of New Jersey.
Dr. Giampapa has filed or been awarded over 24 US patents for regenerative medicine technologies, stem cell reprogramming and more. He is the recipient of the Edison Award for the Healthycell nutritional supplement for cell health, and of the A4M Science & Technology Award for his development of the BioMarker Matrix Profile -- the first computer program to measure aging. Dr. Giampapa has served as a NASA consultant for the space shuttle robotic arm, and has worked as a medical consultant to Allergan Medical (NYSE: AGN), Medicis Pharmaceutical Corporation, and Sanofi-Aventis (NYSE: SNY).
Dr. Giampapa received his medical degree from Mt. Sinai Medical School in New York, New York and continued his medical training in plastic surgery at St. Luke's and Columbia Presbyterian Hospitals in New York. He is published in numerous academic journals including the Annals of Plastic Surgery, the Journal of Plastic and Reconstructive Surgery, The Journal of Reconstructive Microsurgery, The Journal of Anti-Aging Medicine, and The Journal of Stem Cells and Development. He is the author of the first and only medical textbook for physicians on Anti-Aging Medicine and Age Management. He has also authored five books for the general public on the topic including; Breaking the Aging Code (Basic Health Publications) and The Anti-Aging Solution: 5 Simples Steps to Looking and Feeling Young (Wiley), The Gene Makeover, The 21st Century Anti-Aging Breakthrough, Quantum Longevity, and Pro-Hormone Nutrition-Optimum Aging & Maximum Health Span with Nature's Hormone-Enhancing Nutrients, and Younger Today, coauthored with Carol Alt.
About American CryoStem Corporation
Founded in 2008, American CryoStem Corporation (OTC PINK: CRYO) is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of regenerative and personalized medicine. The Company has developed Standard Operating Procedures (SOPs) to operate state-of-art, FDA-registered, clinical laboratories dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs). Leveraging its Institutional Review Board (IRB) approved platform technologies with a portfolio of developed products, the Company is building a global network of licensed laboratory affiliates and physician networks to deliver current and future cellular applications. The Company maintains a portfolio of intellectual property that forms the foundation of its standardized platform and products which support a growing pipeline of stem cell applications and biologic products. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies. For additional information, please visit www.americancryostem.com and www.acslaboratories.com.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Vice President, Investor Relations